Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

9784	Companies
196006	Keywords
127061	Articles
104236	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 6 months ago

THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET " PACTE DE RECHERCHE 2024 " DE LA REGION AUVERGNE-RHÔNE-ALPES
Theranexus, CRNL, and CERMEP win 'Pacte de recherche 2024' project in Auvergne-Rhône-Alpes to develop new neuroimaging tools for rare neurological diseases treatment

Theranexus Rare Neurological Diseases Neuroimaging CRNL CERMEP
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 6 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 7 months ago

Theranexus et BBDF annoncent des résultats positifs à 18 mois pour Batten-1 dans une étude de phase 1/2

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 06/06/2024 at 07:35, 1 year 7 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 7 months ago

Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3)

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 7 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 1 year 9 months ago

Theranexus dévoile son document d'enregistrement universel pour 2023

2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares
BRIEF

published on 05/02/2024 at 07:35, 1 year 9 months ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
PRESS RELEASE

published on 05/02/2024 at 07:30, 1 year 9 months ago

MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
Theranexus annonce le dépôt de son document d'enregistrement universel pour l'exercice 2023, disponible sur son site. Theranexus se spécialise dans le traitement des maladies neurologiques rares

Biopharmaceutique Theranexus Maladies Neurologiques Rares Dépôt Document D'enregistrement Universel Neurones Et Cellules Gliales
BRIEF

published on 04/29/2024 at 18:25, 1 year 9 months ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease

Accesswire

Published on 02/02/2026 at 23:25, 20 minutes ago

Western Announces Sale of GlassMasters Investment
Published on 02/02/2026 at 22:05, 1 hour 40 minutes ago

Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 8 hours 45 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform
Published on 02/02/2026 at 14:30, 9 hours 15 minutes ago

Unusual Machines Promotes Drew Camden to President
Published on 02/02/2026 at 14:30, 9 hours 15 minutes ago

Predictiv AI Provides Pilot Update from Innovate Calgary's Soaring Higher Challenge with Calgary Airports and WestJet

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 3 hours 45 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 3 hours 48 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 4 hours 2 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 4 hours 40 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 4 hours 45 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 5 hours 21 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 5 hours 21 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 5 hours 45 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 5 hours 45 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 5 hours 45 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE